Toronto Dominion Bank Aeterna Zentaris Inc. Transaction History

Toronto Dominion Bank

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 11, 2022	BUY	$0.17 - $0.37 $1,899 - $4,135	11,176 Added 37.72%	40,801 $8,000
Q1 2022 May 09, 2022	SELL	$0.33 - $0.42 $486 - $619	-1,475 Reduced 4.74%	29,625 $11,000
Q4 2021 Feb 04, 2022	BUY	$0.36 - $0.77 $6,300 - $13,475	17,500 Added 128.68%	31,100 $11,000
Q3 2021 Nov 08, 2021	BUY	$0.59 - $0.88 $1,593 - $2,376	2,700 Added 24.77%	13,600 $10,000
Q2 2021 Aug 13, 2021	BUY	$0.83 - $1.14 $9,047 - $12,425	10,900 New	10,900 $9,000

Ticker AEZS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 4,855,880
Market Cap $19.4M
Description
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult grow...

Get notified when there are updates to the investment portfolio of Toronto Dominion Bank, based on Form 13F filings with the SEC.

Stay updated on Toronto Dominion Bank with notifications on news.